An Updated Pooled Analysis of Off-Label Under and Over-Dosed Direct Oral Anticoagulants in Patients with Atrial Fibrillation

Author:

Shen Nan-Nan1,Ferroni Eliana2,Amidei Claudio Barbiellini2,Canova Cristina3,Peron Viviana3,Wang Jia-Liang1,Lin Hou-Wen4,Gu Zhi-Chun4ORCID

Affiliation:

1. Department of Pharmacy, Affiliated Hospital of Shaoxing University, Shao Xing, China

2. Epidemiological Department, Veneto Region, Venezia, Italy

3. Department of Cardio-Thoraco-Vascular Sciences and Public Health, University of Padua, Padova, Italy

4. Department of Pharmacy, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Abstract

Introduction Off-label, under-, and overdosed direct oral anticoagulants (DOACs) are commonly prescribed to patients with atrial fibrillation (AF), but real-world evidence on their effectiveness and safety is limited. Methods MEDLINE, Embase, and Cochrane Library databases were systematically searched from 01 July 2020 to 28 February 2022 to update a previous systematic review with the same search strategy from the inception to 30 June 2020. Eligible studies were those that reported effectiveness (stroke/systemic embolism and myocardial infarction) or safety (gastrointestinal or major bleeding and death) outcomes of off-label doses of DOACs compared to on-label doses in AF patients. A random-effects meta-analysis was performed to estimate the pooled hazard ratio (HR) and 95% confidence interval (CI). Subgroup analyses were performed by specific DOACs and geographic regions. Results Twenty-two studies were included. Off-label, underdosed DOACs, compared to on-label doses, were not associated with an increased risk of stroke (HR 1.03, 95%CI: 0.88-1.17) but were associated with an increased risk of death (HR 1.26, 95%CI: 1.09-1.43). However, risk varied depending on the active ingredient. No other safety outcomes were associated with underdosed DOACs. No significant differences were observed by geographic regions. Compared to on-label DOACs, overdosing increased the risk of stroke (HR 1.17, 95%CI: 1.04-1.31), major bleeding (HR 1.18, 95%CI: 1.05-1.31), and death (HR 1.19, 95%CI: 1.03-1.35). Risk varied between geographical regions. Conclusions Off-label underdoses, compared to on-label dosing of DOACs, did not increase the risk of stroke but did increase overall mortality. Overdosed DOACs, compared to on-label doses, were associated with an increased risk of stroke, major bleeding, and death. Future studies must examine these associations, focusing on specific active ingredients and geographic settings.

Funder

Clinical Research Innovation and Cultivation Fund of Ren Ji hospital

Clinical Medical Research Special Fund Project of Zhejiang Medical Association

the Research Project of Drug Clinical Comprehensive Evaluation and Drug Treatment Pathway

the Program of General Scientific Project of Zhejiang Education Department

Research Project of Grassroots health science of Zhejiang Province

Ren Ji Boost Project of National Natural Science Foundation of China

Publisher

SAGE Publications

Subject

Hematology,General Medicine

Reference42 articles.

1. Atrial Fibrillation - Centers for Disease Control and Prevention. https://www.cdc.gov/heartdisease/atrial_fibrillation.htm#:∼:text=Atrial%20fibrillation%2C%20often%20called%20AFib,or%20in%20an%20irregular%20way

2. Dabigatran versus Warfarin in Patients with Atrial Fibrillation

3. Apixaban versus Warfarin in Patients with Atrial Fibrillation

4. Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

5. Edoxaban versus Warfarin in Patients with Atrial Fibrillation

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3